Further, AIB1 may increase anti-hormone therapy resistance and enhance breast cancer stem cell activity by promoting metabolic plasticity through interaction with PELP1 (75) and contribute to BC metastasis under these therapy resistant conditions by inhibiting CDH1 (E-cadherin) (89). Here, NCOA3 is linked to breast carcinoma.